{
  "catalysts": [
    {
      "ticker": "KRYS",
      "current_price": 248.91,
      "market_cap": "$7.2B",
      "conviction_score": 8,
      "thesis": "Positive interim Phase 1 data for KB407 validates the company's redosable gene therapy platform in Cystic Fibrosis, a major new indication. Despite analyst upgrades to $309 (Citigroup) and $272 (BofA), the stock has only moved ~1-2%, leaving the catalyst largely unpriced.",
      "catalyst_details": "On Jan 8, 2026, Krystal Biotech announced positive interim results from the Phase 1 CORAL-1 study, confirming successful lung delivery and expression of wild-type CFTR protein.",
      "absorption_status": "Muted +1% reaction suggests the market is underestimating the platform validation; price is consolidating while analysts aggressively raise targets.",
      "earnings_date": "2026-02-23",
      "relative_volume": "1.2x",
      "stop_loss_trigger": "$235.44 (1.5 ATR)",
      "sentiment": "Bullish",
      "prediction_market": "High confidence in platform expansion.",
      "recency_proof": "https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-interim-clinical-update-kb407",
      "risk": "Early-stage clinical risk; liquidity in gene therapy sector.",
      "expected_upside": "20-25% (Target $309) | Target: $275.85",
      "mispricing_evidence": "Analyst price target upgrades to $309 following data release contrast with flat/marginal price action.",
      "x_sentiment": "Positive buzz on $KRYS platform validation.",
      "atr_value": 8.98,
      "calculated_stop_loss": 235.44,
      "calculated_target": 275.85
    }
  ]
}